← Harbin Pharmaceutical overview

Harbin Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Harbin Pharmaceutical Group Co Ltd (600664.CG)

Q3 2026
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

August 2026
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Latest
▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

  • National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.

    This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.

  • Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.

    Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.

  • Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.

    Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.

  • New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.

    This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.